Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Next Previous
Trial Profile

PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CP 101 Finch Therapeutics Group (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRISM-EXT
  • Sponsors Finch Research & Development

    • Most Recent Events

    • 26 Oct 2022 Results assessing the safety and efficacy of CP101 for the Prevention of Recurrent C. difficile Infection presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 24 Oct 2022 According to a Finch Therapeutics Group media release, biomarker data from this study were presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
    • 24 Oct 2022 Results presented in a Finch Therapeutics Group media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top